The purpose of the Administrative Core is to support the translational research objectives of our SPORE in Prostate Cancer by serving as the organizational hub, optimizing collaboration among SPORE investigators within and outside the MSKCC.
The specific aims of the Administrative Core are (1) provide coordination for all educational and scientific activities of the SPORE, and (2) provide centralized administrative support of day-today activities to all the components of the SPORE: research projects, cores, and developmental programs. The services centralized in the Administrative Core provide the following administrative and communications infrastructure that serve all components of the SPORE. ? Financial Management: serving as the centralized SPORE budgetary coordinator and financial manager ? Editorial Services: providing editorial services for manuscript publication and grants coordination ? Grants Administration: serve as administrative liaison to the National Cancer Institute, ensuring the timely submission of all required reports and compliance with institutional and federal regulations ? Meetings Coordination: organize the scientific review of ongoing SPORE research projects, cores, and pilot projects as well as the annual solicitation of new pilot projects ? Communication: foster communication and collaborative research within our SPORE as well as with other SPOREs in Prostate Cancer, the Prostate Cancer Clinical Trials Consortium (PCCTC), the clinical trials mechanism for the SPOREs in Prostate Cancer, and the wider scientific community ? Data Management System Support: manage and support the clinical research database, Caisis The Administration Core is led by Howard I. Scher, MD, who oversees all SPORE activities. The Core?s codirectors, Peter T. Scardino, MD, Charles L. Sawyers, MD, and Philip Kantoff, MD, will assist Dr. Scher. The Administrative Core also includes personnel trained in financial management, grants administration, medical editing, data management, and clerical support.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA092629-19
Application #
9774804
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2019-09-01
Budget End
2020-08-31
Support Year
19
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Puca, Loredana; Bareja, Rohan; Prandi, Davide et al. (2018) Patient derived organoids to model rare prostate cancer phenotypes. Nat Commun 9:2404
Currall, Benjamin B; Chen, Ming; Sallari, Richard C et al. (2018) Loss of LDAH associated with prostate cancer and hearing loss. Hum Mol Genet 27:4194-4203
Armenia, Joshua; Wankowicz, Stephanie A M; Liu, David et al. (2018) The long tail of oncogenic drivers in prostate cancer. Nat Genet 50:645-651
Chen, Yu; Chi, Ping (2018) Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers. J Hematol Oncol 11:78
McDevitt, Michael R; Thorek, Daniel L J; Hashimoto, Takeshi et al. (2018) Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. Nat Commun 9:1629
Audenet, François; Vertosick, Emily A; Fine, Samson W et al. (2018) Biopsy Core Features are Poor Predictors of Adverse Pathology in Men with Grade Group 1 Prostate Cancer. J Urol 199:961-968
Hugosson, Jonas; Godtman, Rebecka Arnsrud; Carlsson, Sigrid V et al. (2018) Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality. Scand J Urol 52:27-37
Kohestani, Kimia; Chilov, Marina; Carlsson, Sigrid V (2018) Prostate cancer screening-when to start and how to screen? Transl Androl Urol 7:34-45
Ankerst, Donna P; Straubinger, Johanna; Selig, Katharina et al. (2018) A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts. Eur Urol 74:197-203
Kim, Kwanghee; Watson, Philip A; Lebdai, Souhil et al. (2018) Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts. Clin Cancer Res 24:2408-2416

Showing the most recent 10 out of 505 publications